← RIGEL PHARMACEUTICALS INC (RIGL) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
RIGEL PHARMACEUTICALS INC (RIGL)
Pharmaceutical Preparations · market cap $890M · as of 2026-07-22
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-03 (est.)
Earnings
Pipeline
14
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Rigel Pharmaceuticals (RIGL) is a small-cap pharma with 162 employees and a ~$734M market cap built around fostamatinib, an oral SYK inhibitor with an approved indication in immune thrombocytopenic purpura (ITP) and an active Phase 3 trial in lymphoma. The company posted $294M in revenue and $367M in net income in 2025—a sharp inflection versus prior losses—but carries only $24.4M in cash against $43.1M in net debt, raising near-term liquidity questions.
The catalyst path
- 2026-11-03 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Fostamatinib Disodium / R935788 | Phase 2 | Purpura, Thrombocytopenic, Idiopathic |
| R788 | Phase 2 | Rheumatoid Arthritis |
| Fostamatinib 150 mg | Phase 2 | IGA Nephropathy |
| fostamatinib | Phase 3 | Lymphoma |
| Fostamatinib 150 mg bid | Phase 2 | Warm Antibody Autoimmune Hemolytic Anemia |
| Fostamatinib disodium (R935788) | Phase 2 | Rheumatoid Arthritis |
| R906289 Monosodium (R289 Na) | Phase 2 | Low Risk Myelodysplastic Syndromes |
| R940343 1mg | Phase 2 | Asthma |
| R348 Ophthalmic Solution, 0.2% | Phase 2 | Keratoconjunctivitis Sicca |
| Olutasidenib + TMZ | Phase 2 | High Grade Glioma |
| Fostamatinib disodium | Phase 3 | Immune Thrombocytopenic Purpura |
| R932333 | Phase 2 | Lupus Erythematosus, Discoid |
| R348 Ophthalmic Solution, 0.5% | Phase 2 | Chronic Graft-versus-host Disease |
| R926112 | Phase 2 | Rhinitis, Allergic, Seasonal |
Price & technical context
3-month
+21.3%
6-month
+70.8%
12-month
+65.8%
52-wk range
$25.44–$50.96
vs 50-day MA
+6.1%
vs 200-day MA
+28.6%
Realized vol
60.9%
Max drawdown
-50.1%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for RIGL (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 14 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.